PLN-101095 is under clinical development by Pliant Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PLN-101095’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PLN-101095 overview

PLN-101095 is under development for the treatment of solid tumor. The drug candidate acts by targeting integrin alpha V  beta 8 and integrin alpha V  beta 1. It is administered through oral route.

Pliant Therapeutics overview

Pliant Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of fibrosis. The company’s pipeline products include PLN-74809, PLN-101095, PLN-101325 and PLN-1474. Its pipeline candidates treat idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), solid tumors, other muscular dystrophies and NASH-associated liver fibrosis. The company is also evaluating therapies to treat muscular dystrophy, solid tumors, and cancer. It works in partnership with Novartis AG and other institutions, universities, medical centers, physicians and researchers to develop its products. Pliant Therapeutics is headquartered in South San Francisco, California, the US.

For a complete picture of PLN-101095’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.